Oruka Therapeutics (ORKA) Competitors $12.50 +0.55 (+4.60%) Closing price 04:00 PM EasternExtended Trading$12.44 -0.06 (-0.52%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA vs. APGE, MESO, VERA, GLPG, KNSA, SDGR, AAPG, IDYA, WVE, and IMCRShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Apogee Therapeutics (APGE), Mesoblast (MESO), Vera Therapeutics (VERA), Galapagos (GLPG), Kiniksa Pharmaceuticals (KNSA), Schrödinger (SDGR), Ascentage Pharma Group International (AAPG), IDEAYA Biosciences (IDYA), Wave Life Sciences (WVE), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Apogee Therapeutics Mesoblast Vera Therapeutics Galapagos Kiniksa Pharmaceuticals Schrödinger Ascentage Pharma Group International IDEAYA Biosciences Wave Life Sciences Immunocore Apogee Therapeutics (NASDAQ:APGE) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Does the media prefer APGE or ORKA? In the previous week, Apogee Therapeutics had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 5 mentions for Apogee Therapeutics and 1 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.89 beat Apogee Therapeutics' score of 1.45 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Apogee Therapeutics Positive Oruka Therapeutics Very Positive Which has better valuation & earnings, APGE or ORKA? Apogee Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$83.99M-$3.29-12.07Oruka TherapeuticsN/AN/A-$5.34M-$5.79-2.16 Do institutionals and insiders believe in APGE or ORKA? 79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer APGE or ORKA? Apogee Therapeutics received 11 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformApogee TherapeuticsOutperform Votes28100.00% Underperform VotesNo VotesOruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo Votes Do analysts prefer APGE or ORKA? Apogee Therapeutics presently has a consensus target price of $92.17, suggesting a potential upside of 132.04%. Oruka Therapeutics has a consensus target price of $39.86, suggesting a potential upside of 218.86%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has more risk & volatility, APGE or ORKA? Apogee Therapeutics has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Is APGE or ORKA more profitable? Apogee Therapeutics' return on equity of -21.81% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -21.81% -20.94% Oruka Therapeutics N/A -24.96%-21.22% SummaryApogee Therapeutics beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$468.01M$2.42B$5.64B$7.83BDividend YieldN/A0.72%4.57%4.00%P/E Ratio-2.006.1123.1418.67Price / SalesN/A46.03388.4891.04Price / CashN/A15.7538.1634.64Price / BookN/A2.986.894.23Net Income-$5.34M-$65.73M$3.20B$247.15M7 Day Performance3.31%-4.49%-2.98%-2.19%1 Month Performance23.15%-10.52%1.67%-5.68%1 Year PerformanceN/A-25.44%9.87%-0.67% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics3.1789 of 5 stars$12.50+4.6%$39.86+218.9%N/A$468.01MN/A-2.00N/APositive NewsAPGEApogee Therapeutics2.408 of 5 stars$40.84+2.5%$92.17+125.7%-42.4%$1.84BN/A-16.8891Positive NewsMESOMesoblast1.8078 of 5 stars$14.39+3.2%$18.00+25.1%+281.1%$1.83B$5.67M0.0080Gap DownVERAVera Therapeutics3.089 of 5 stars$27.15+0.3%$64.67+138.2%-39.5%$1.73BN/A-10.4040GLPGGalapagos0.7205 of 5 stars$25.95+0.5%$26.75+3.1%-22.6%$1.71B$275.65M0.001,123News CoveragePositive NewsKNSAKiniksa Pharmaceuticals2.9796 of 5 stars$23.41+0.2%$37.17+58.8%+16.9%$1.70B$423.24M-167.20220SDGRSchrödinger2.6137 of 5 stars$22.75+4.4%$32.29+41.9%-23.9%$1.66B$207.54M-9.72790Positive NewsGap UpAAPGAscentage Pharma Group InternationalN/A$18.97+1.4%N/AN/A$1.65B$903.03M0.00600Analyst ForecastNews CoverageGap UpIDYAIDEAYA Biosciences3.5845 of 5 stars$18.59+1.1%$53.58+188.2%-59.8%$1.63B$7M-5.6380News CoveragePositive NewsWVEWave Life Sciences4.5576 of 5 stars$10.07+5.0%$22.60+124.4%+49.2%$1.55B$108.30M-9.07240Analyst ForecastNews CoverageIMCRImmunocore1.9208 of 5 stars$29.64-0.6%$65.64+121.4%-52.6%$1.48B$310.20M-31.20320 Remove Ads Related Companies and Tools Related Companies APGE Competitors MESO Competitors VERA Competitors GLPG Competitors KNSA Competitors SDGR Competitors AAPG Competitors IDYA Competitors WVE Competitors IMCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORKA Stock Free ORKA Stock Alerts